8 completed, 5 active not recruiting, 5 recruiting, 4 terminated. 25 Phase 3, 8 Phase 2.
Follow Neuromyelitis Optica: new trials by email Literature Review of Neuromyelitis Optica trials Research Report on Neuromyelitis Optica
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy, Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity Study of Ravulizumab in Chinese Adults With Neuromyelitis Optica Spectrum Disorder (NMOSD) Ravulizumab - NMOSD, Neuromyelitis Optica Spectrum Disorder | Phase 3 | Recruiting | Alexion Pharmaceuticals, Inc. | 19 | 2026-07-20 | 2026-09-11 |
| A Study to Evaluate Pharmacokinetics, Efficacy, Safety, Tolerability, and Pharmacodynamics of Satralizumab in Pediatric Patients With Aquaporin-4 Antibody Positive Neuromyelitis Optica Spectrum Disorder (NMOSD) Satralizumab - Neuromyelitis Optica Spectrum Disorder, NMOSD | Phase 3 | Recruiting | Hoffmann-La Roche | 8 | 2026-05-06 | 2026-10-01 |
| Modified Zipper Therapy for AQP4-IgG Positive Neuromyelitis Optica Spectrum Disorder Eculizumab administration, High-dose corticosteroid pulse therapy, Plasma exchange (PE) - Neuromyelitis Optica Spectrum Disorders (NMOSD) | Phase 3 | Recruiting | Tianjin Medical University General Hospital | 198 | 2026-01-01 | 2026-05-14 |
| Slow vs. Rapid Glucocorticoids Tapering With Inebilizumab in NMOSD Slow-tapering glucocorticoids + Inebilizumab, Rapid-tapering glucocorticoids + Inebilizumab - Neuromyelitis Optica (NMO), Neuromyelitis Optica Spectrum Disorders (NMOSD) | Phase 3 | Not yet recruiting | Tianjin Medical University General Hospital | 170 | 2025-09-01 | 2025-08-20 |
| Efficacy, Safety, PK, PD, and ADA of Eculizumab in Chinese Adults With NMOSD eculizumab - NMOSD, Neuromyelitis Optica Spectrum Disorders | Phase 3 | Active not recruiting | Alexion Pharmaceuticals, Inc. | 21 | 2025-01-16 | 2025-12-19 |
| A Clinical Study of B001 Injection in the Treatment of Neuromyelitis Optica Spectrum Disorders(NMOSD) B001, Placebo - Neuromyelitis Optica Spectrum Disorders | Phase 2 / Phase 3 | Recruiting | Shanghai Jiaolian Drug Research and Development Co., Ltd | 132 | 2024-07-17 | 2026-05-05 |
| Azathioprine in MOGAD Azathioprine, Placebo - Central Nervous System Inflammation, MOG-IgG Associated Disease | Phase 3 | Recruiting | Hospices Civils de Lyon | 126 | 2023-12-12 | 2025-02-04 |
| Efficacy and Safety of Divozilimab in Patients With Neuromyelitis Optica Spectrum Disorders (AQUARELLE) divozilimab - Neuromyelitis Optica Spectrum Disorders | Phase 3 | Active not recruiting | Biocad | 105 | 2022-12-12 | 2024-11-07 |
| Safety and Efficacy of Daratumumab in Patients With Anti-Aquaporin 4 Antibody Positive Neuromyelitis Optica Spectrum Disorders Daratumumab, Placebo - Neuromyelitis Optica, Neuromyelitis Optica Spectrum Disorder | Phase 2 / Phase 3 | Active not recruiting | Tianjin Medical University General Hospital | 135 | 2022-11-01 | 2025-03-30 |
| A Study of MIL62 in Patients With Neuromyelitis Optica Spectrum Disorder (NMOSD) MIL62, Placebo - Neuromyelitis Optica Spectrum Disorder | Phase 3 | Active not recruiting | Beijing Mabworks Biotech Co., Ltd. | 102 | 2022-08-18 | 2025-09-25 |
| Efficacy and Safety Study of Ravulizumab IV in Pediatric Participants With NMOSD Ravulizumab - Neuromyelitis Optica Spectrum Disorder | Phase 2 / Phase 3 | Active not recruiting | Alexion Pharmaceuticals, Inc. | 12 | 2022-06-23 | 2026-06-24 |
| A Study to Evaluate the Safety and Efficacy of Satralizumab in Participants With Neuromyelitis Optica Spectrum Disorder (NMOSD) satralizumab, azathioprine (AZA), mycophenolate mofetil (MMF) - Neuromyelitis Optica Spectrum Disorder | Phase 3 | Completed | Hoffmann-La Roche | 119 | 2021-03-02 | 2024-12-27 |
| A Study of the Safety and Activity of Eculizumab in Pediatric Participants With Relapsing Neuromyelitis Optica Spectrum Disorder Eculizumab - Neuromyelitis Optica, Neuromyelitis Optica Spectrum Disorder | Phase 2 / Phase 3 | Terminated | Alexion Pharmaceuticals, Inc. | 5 | 2020-01-14 | 2024-09-25 |
| An Efficacy and Safety Study of Ravulizumab in Adult Participants With NMOSD Ravulizumab - Neuromyelitis Optica, Neuromyelitis Optica Spectrum Disorder | Phase 3 | Completed | Alexion Pharmaceuticals, Inc. | 58 | 2019-12-09 | 2025-10-14 |
| Autologous Transplant To End NMO Spectrum Disorder Rituximab, Cyclophosphamide, Mesna - Neuromyelitis Optica, Devic's Disease | Phase 2 / Phase 3 | Withdrawn | Northwestern University | 2019-11-01 | 2019-11-20 | |
| A Phase III Study of TACI-antibody Fusion Protein Injection (RC18) in Subjects With Neuromyelitis Optica Spectrum Disorders Placebo, RC18 160 mg - Neuromyelitis Optica Spectrum Disorders | Phase 3 | Terminated | RemeGen Co., Ltd. | 178 | 2018-01-29 | 2026-04-13 |
| Tocilizumab vs Azathioprine in Neuromyelitis Optica Spectrum Disorders Tocilizumab Injection, Azathioprine - Neuromyelitis Optica Spectrum Disorders, Neuromyelitis Optica | Phase 2 / Phase 3 | Completed | Tianjin Medical University General Hospital | 118 | 2017-11-01 | 2019-10-24 |
| Comparison of Clinical Effects of Azathioprine and Rituximab NMO-SD Patients Azathioprine, Rituximab - Neuromyelitis Optica Spectrum Disorder | Phase 2 / Phase 3 | Completed | Isfahan University of Medical Sciences | 86 | 2015-09-01 | 2020-09-30 |
| N-MOmentum: A Clinical Research Study of Inebilizumab in Neuromyelitis Optica Spectrum Disorders Inebilizumab, Placebo - Neuromyelitis Optica and Neuromyelitis Optica Spectrum Disorders | Phase 2 / Phase 3 | Completed | MedImmune LLC | 231 | 2015-04-01 | 2021-12-03 |
| A Multicentre randomiSed Controlled TRial of IntraVEnous Immunoglobulin Versus Standard Therapy for Transverse Myelitis Intravenous Methylprednisolone, Intravenous Immunoglobulin - Myelitis, Transverse, Neuromyelitis Optica | Phase 3 | Terminated | Guy's and St Thomas' NHS Foundation Trust | 2 | 2015-03-01 | 2016-07-20 |
Showing 20 of 25. Sign in to see all of them.
Myelitis, Transverse (6) · Optic Neuritis (6) · Demyelinating Diseases (5) · Recurrence (4) · Diffuse Cerebral Sclerosis of Schilder (1) · Encephalomyelitis, Acute Disseminated (1) · Mental Disorders (1) · Multiple Sclerosis (1) · Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (1) · Myelitis (1) · Neurologic Manifestations (1) · Rare Diseases (1)
Autoimmune Diseases (25) · Autoimmune Diseases of the Nervous System (25) · Cranial Nerve Diseases (25) · Demyelinating Autoimmune Diseases, CNS (25) · Eye Diseases (25) · Immune System Diseases (25) · Nervous System Diseases (25) · Optic Nerve Diseases (25) · Demyelinating Diseases (20) · Myelitis, Transverse (19) · Optic Neuritis (19) · Central Nervous System Diseases (7) · Central Nervous System Infections (7) · Infections (7) · Neuroinflammatory Diseases (7)
Azathioprine (4) · eculizumab (4) · satralizumab (4) · ravulizumab (3) · Immunoglobulins, Intravenous (2) · Plasma Exchange (2) · Rituximab (2) · inebilizumab (2) · Adrenal Cortex Hormones (1) · Antilymphocyte Serum (1) · Cyclophosphamide (1) · Filgrastim (1) · Granulocyte Colony-Stimulating Factor (1) · Immunoglobulin G (1) · Mesna (1)
Alexion Pharmaceuticals, Inc. (7) · Hoffmann-La Roche (4) · Tianjin Medical University General Hospital (4) · Beijing Mabworks Biotech Co., Ltd. (1) · Biocad (1) · Guy's and St Thomas' NHS Foundation Trust (1) · Hospices Civils de Lyon (1) · Isfahan University of Medical Sciences (1) · MedImmune LLC (1) · National Institute of Neurological Disorders and Stroke (NINDS) (1) · Northwestern University (1) · RemeGen Co., Ltd. (1) · Shanghai Jiaolian Drug Research and Development Co., Ltd (1)
United States (11) · China (9) · Italy (9) · Japan (8) · South Korea (8) · Spain (8) · Canada (7) · Germany (7) · United Kingdom (7) · Poland (6) · Taiwan (6) · Turkey (Türkiye) (6) · France (5) · Australia (4) · Croatia (4)
Brian G. Weinshenker (1) · Fu-Dong Shi, MD,PhD (1) · Ming Lim, MB, PhD (1) · Richard Burt, MD (1) · Vahid Shaygannejad, M.D. (1) · Xiangjun Chen, M.D (1)
PMID 40743487, PMID 33676197, PMID 34498507, PMID 36007339, PMID 36724181, PMID 40288333, PMID 26009577, PMID 26666258, PMID 28639937, PMID 28831548, PMID 31050279, PMID 31495497, PMID 31774956, PMID 32333897, PMID 32333898, PMID 33310418, PMID 33538237, PMID 33724534, PMID 33771837, PMID 34803867, PMID 35158461, PMID 36370634, PMID 37221052, PMID 38356884, PMID 38760098, PMID 39222408, PMID 41782198, PMID 42177718, PMID 42441931, PMID 42575985
2019 (3), 2014 (2), 2015 (1), 2023 (1)